B-cell Non-Hodgkin's Lymphoma Clinical Trial
Official title:
Study of Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).
Chidamideļ¼a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide combined with DICE in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00588094 -
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
|
Phase 2 | |
| Not yet recruiting |
NCT05091541 -
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03639181 -
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
|
Phase 2 | |
| Recruiting |
NCT06104553 -
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT01352312 -
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT05771883 -
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06314828 -
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
|
Phase 1 | |
| Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
| Suspended |
NCT04697290 -
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
|
Early Phase 1 | |
| Completed |
NCT02564744 -
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
|
Phase 2 | |
| Recruiting |
NCT05453669 -
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL
|
Phase 1 | |
| Recruiting |
NCT05190068 -
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Suspended |
NCT04746131 -
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
|
Phase 1 | |
| Active, not recruiting |
NCT00927797 -
Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)
|
Phase 2 | |
| Recruiting |
NCT05436223 -
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Completed |
NCT00457782 -
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
|
Phase 1 |